Insurance access tool
GLP-1 Prior Authorization Letter Generator
Two minutes gets you a draft prior authorization letter for Foundayo, Saxenda, Zepbound or Wegovy. It is built from the indication language in the FDA label, whichever pivotal trial citation applies, and the step-therapy documentation most US insurers ask for. Pass the draft to your prescribing clinician; reviewing, editing, signing and submitting are theirs to do.
DRAFT — the prescribing clinician must review and sign this before it is submitted. Not legal or medical advice.
A template letter is what comes out of this generator, for the prescribing clinician to review, edit and sign. No medical advice is given here and no coverage is guaranteed. Your browser generates the letter in full: nothing you type is transmitted or stored.
Computed from your weight + height: 31.9
Generated PA letter
[Date] Aetna Pharmacy Prior Authorization Department Re: Prior Authorization Request Patient: [Patient Name] Date of Birth: [DOB] Height: 5 ft 8 in Current Weight: 210 lbs BMI: 31.9 kg/m² Requested Medication: Wegovy (semaglutide) 2.4 mg subcutaneous once weekly Requested Quantity: four (4) single-dose 2.4 mg pens per 28 days To Whom It May Concern, This is a request for prior authorization coverage of Wegovy (semaglutide) 2.4 mg subcutaneous once weekly, on behalf of the patient named above, for chronic weight management — an FDA-approved indication. FDA-Approved Indication. Wegovy (semaglutide) is FDA-approved, alongside a lower-calorie diet and more exercise, to bring excess weight down and keep it down over the long term, in adults who have obesity or who are overweight with at least one weight-related comorbid condition. In the pivotal trials behind the label, obesity meant a BMI of 30 kg/m² or higher and overweight a BMI from 27 up to 30 kg/m²; payer criteria use those same cut-offs. Wegovy is additionally FDA-approved (i) to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight (SELECT trial, FDA-approved March 2024), and (ii) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (stage F2-F3) in conjunction with diet and physical activity (ESSENCE trial, FDA accelerated approval August 2025). If the patient's primary qualifying condition is established CVD or biopsy/imaging-confirmed MASH with fibrosis, submit under that indication. Patient Eligibility. At a documented 31.9 kg/m², this patient meets the obesity definition (BMI ≥ 30 kg/m²) used in the label's pivotal trials and in plan criteria. Documented alongside that, this patient carries the following weight-related comorbid condition(s): Type 2 diabetes mellitus (ICD-10 E11.9). Clinical Rationale. Level 1 evidence out of the STEP-1 pivotal trial supports Wegovy. STEP-1 (Wilding et al., NEJM 2021) demonstrated mean total body weight loss of 14.9% over 68 weeks at the 2.4 mg maintenance dose. Read together, this patient's BMI and their documented comorbid burden put them squarely inside the FDA-approved population that trial studied, and what is requested here is the labeled maintenance dose. Step Therapy and Prior Treatment History. Ahead of this request the patient has on record the weight management attempts listed below, not one of which produced weight loss that was either sustained or clinically meaningful: supervised reduced-calorie dietary intervention of at least 6 months duration and structured physical activity program of at least 150 minutes per week sustained for 6 months. Together they document the prior-treatment history that step therapy calls for. Plan-Specific Note. Aetna's pharmacy PA criteria for weight-management GLP-1s set the baseline BMI floor at 30 kg/m² (27 kg/m² where a weight-related comorbidity exists) and look for at least six months in a structured weight-loss program, built on behavior change, calorie reduction and exercise with ongoing follow-up, before medication starts. Both are documented in this letter. Attestation. On the BMI and comorbidity documentation above, this patient falls within the FDA-approved population and the plan's BMI criteria. This patient was evaluated by me personally, and everything set out above is accurate so far as I know it. Weight, vital signs and adverse effects will go on being monitored per standard of care. I will reassess weight-loss response once the patient is at the maintenance dose and will discontinue therapy if the response does not meet the plan's reauthorization criteria. Requested Action. Approve Wegovy 2.4 mg subcutaneous once weekly for the plan's initial authorization period, with reauthorization thereafter to turn on documented weight-loss response. With thanks for reviewing this promptly. Any questions, or any further documentation required, please reach my office. Sincerely, [Prescribing Clinician Name, Credentials] Prescribing Clinician _________________________________ Signature Date DRAFT — the prescribing clinician must review and sign this before it is submitted. Not legal or medical advice.
Prior authorization, and why a GLP-1 sets one off
Prior authorization (PA) is a utilization management rule insurers use to control spending on high-cost drugs. For brand GLP-1 weight-loss medications — Wegovy, Zepbound, Saxenda, and the newly approved Foundayo — virtually every US commercial plan requires PA before paying any portion of the prescription. The reason is simple: list prices are as much as $1,349 per monthly fill, so a covered patient on therapy for a year can represent about $17,500 of annual plan spend.
A complete PA submission has to demonstrate three things: (1) the patient is in the FDA-approved population — adults with obesity, or with overweight plus at least one weight-related comorbidity, which plans read as BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with a comorbidity — (2) prior weight management attempts have been documented to satisfy the plan's step-therapy requirement, and (3) the prescribing clinician attests to the clinical rationale and ongoing monitoring plan. The letter generated by this tool covers all three and uses FDA-label language verbatim where possible.
How to use the generator
- Pick your insurer from the dropdown.
- Choose whichever drug and dose your clinician prescribed.
- Enter your weight and height — BMI auto-computes.
- Check off any documented comorbidities.
- Check off documented prior weight loss attempts (the step-therapy requirement most plans enforce).
- Copy the letter and bring it to your prescribing clinician. They will review, edit, sign, and submit it through the insurer's pharmacy benefit portal.
Your browser assembles the letter and nothing leaves it: what you type is neither transmitted nor stored, and no patient information is logged.
Sample PA letter (Wegovy + BMI 32 + Type 2 diabetes + Aetna)
A worked example. The case that arises most often is an Aetna-covered patient at BMI 32, documented Type 2 diabetes, requesting Wegovy 2.4 mg. Every combination of drug, insurer and comorbidity is handled by the live generator above.
[Date] Aetna Pharmacy Prior Authorization Department Re: Prior Authorization Request Patient: [Patient Name] Date of Birth: [MM/DD/YYYY] Height: 5 ft 8 in Current Weight: 210 lbs BMI: 32.0 kg/m² Requested Medication: Wegovy (semaglutide) 2.4 mg subcutaneous once weekly Requested Quantity: four (4) single-dose 2.4 mg pens per 28 days To Whom It May Concern, This is a request for prior authorization coverage of Wegovy (semaglutide) 2.4 mg subcutaneous once weekly, on behalf of the patient named above, for chronic weight management — an FDA-approved indication. FDA-Approved Indication. Wegovy (semaglutide) is FDA-approved, alongside a lower-calorie diet and more exercise, to bring excess weight down and keep it down over the long term, in adults who have obesity or who are overweight with at least one weight-related comorbid condition. In the pivotal trials behind the label, obesity meant a BMI of 30 kg/m² or higher and overweight a BMI from 27 up to 30 kg/m²; payer criteria use those same cut-offs. Wegovy is additionally FDA-approved (i) to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight (SELECT trial, FDA-approved March 2024), and (ii) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (stage F2-F3) in conjunction with diet and physical activity (ESSENCE trial, FDA accelerated approval August 2025). If the patient's primary qualifying condition is established CVD or biopsy/imaging-confirmed MASH with fibrosis, submit under that indication. Patient Eligibility. At a documented 32.0 kg/m², this patient meets the obesity definition (BMI ≥ 30 kg/m²) used in the label's pivotal trials and in plan criteria. Documented alongside that, this patient carries the following weight-related comorbid condition(s): Type 2 diabetes mellitus (ICD-10 E11.9). Clinical Rationale. Level 1 evidence out of the STEP-1 pivotal trial supports Wegovy. STEP-1 (Wilding et al., NEJM 2021) demonstrated mean total body weight loss of 14.9% over 68 weeks at the 2.4 mg maintenance dose. Read together, this patient's BMI and their documented comorbid burden put them squarely inside the FDA-approved population that trial studied, and what is requested here is the labeled maintenance dose. Step Therapy and Prior Treatment History. Ahead of this request the patient has on record the weight management attempts listed below, not one of which produced weight loss that was either sustained or clinically meaningful: supervised reduced-calorie dietary intervention of at least 6 months duration, structured physical activity program of at least 150 minutes per week sustained for 6 months, and prior trial of phentermine, discontinued for inadequate response or intolerance. Together they document the prior-treatment history that step therapy calls for. Plan-Specific Note. Aetna's pharmacy PA criteria for weight-management GLP-1s set the baseline BMI floor at 30 kg/m² (27 kg/m² where a weight-related comorbidity exists) and look for at least six months in a structured weight-loss program, built on behavior change, calorie reduction and exercise with ongoing follow-up, before medication starts. Both are documented in this letter. Attestation. On the BMI and comorbidity documentation above, this patient falls within the FDA-approved population and the plan's BMI criteria. This patient was evaluated by me personally, and everything set out above is accurate so far as I know it. Weight, vital signs and adverse effects will go on being monitored per standard of care. I will reassess weight-loss response once the patient is at the maintenance dose and will discontinue therapy if the response does not meet the plan's reauthorization criteria. Requested Action. Approve Wegovy 2.4 mg subcutaneous once weekly for the plan's initial authorization period, with reauthorization thereafter to turn on documented weight-loss response. With thanks for reviewing this promptly. Any questions, or any further documentation required, please reach my office. Sincerely, [Prescribing Clinician Name, MD] Prescribing Clinician _________________________________ Signature Date DRAFT — the prescribing clinician must review and sign this before it is submitted. Not legal or medical advice.
Frequently asked questions
What is prior authorization for GLP-1 drugs?
A coverage rule, in short. No plan pays for a brand GLP-1 like Zepbound or Wegovy until your doctor has put clinical documentation in front of the insurer — and nothing else obstructs a brand GLP-1 weight-loss approval as much.
Why is prior auth required for Zepbound and Wegovy?
At list price a brand GLP-1 can run $1,349 a month, and PA is how the insurer satisfies itself on three points before paying: that the FDA label criteria are met, that cheaper weight management came first, and that a clinical rationale is documented. See our GLP-1 insurance coverage audit for how coverage rates actually fall out plan by plan.
How long does prior authorization take?
Most commercial plans process a complete PA submission within 3 to 14 business days. Standard turnaround is about 5 business days; expedited reviews are typically 24 to 72 hours. Incomplete submissions add 1 to 2 weeks of back-and-forth — which is exactly the friction this tool is designed to eliminate.
Does my doctor have to write the PA letter?
Yes — the prescribing clinician is required to author and sign the PA letter; insurers will not accept a letter from the patient. This generator produces a draft template the clinician can review, edit, and sign. See our guide on how to get a GLP-1 prescription.
What if my prior auth is denied?
Appeal — the Affordable Care Act protects that right federally. Denials tend to come down to non-formulary status, no documented prior weight-loss attempts, or missing BMI documentation. Ask for a peer-to-peer review, your doctor to the insurance medical director; it can reverse a denial without a formal appeal.
Does compounded GLP-1 need prior auth?
No. Out of a compounding pharmacy, compounded tirzepatide and semaglutide are paid for out of pocket and never reach your insurance pharmacy benefit, so no PA arises. You forgo insurance coverage for that, and pick up quality and supply risk.
Can I appeal a denial?
Yes — an internal appeal goes to the insurer first, and if it is refused again, an independent external review follows. Federal law allows 180 days from the denial notice for that internal filing. Send the original PA letter along with it, plus further clinical documentation; the case is stronger for both.
How is the BMI requirement enforced?
Insurers verify BMI from the height and weight documented in the most recent clinical visit note. The BMI must be calculated and recorded in the patient's chart before PA submission, not estimated. Wegovy, Zepbound, Saxenda, and Foundayo are all labeled for adults with obesity, or with overweight plus a weight-related comorbidity; plans apply the cut-offs from the pivotal trials, BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with a weight-related comorbidity.
Important disclaimer
What this produces is a draft template, nothing further — not legal advice, not medical advice, and no guarantee that any insurer will cover anything. Nothing goes to an insurer until the prescribing clinician has read, edited and signed it. Where the FDA label supplies wording, that wording is reproduced exactly; where it does not, no clinical recommendation gets invented to fill the gap. GLP Watchdog does not provide medical advice, diagnosis, or treatment recommendations and is not affiliated with any insurer or drug manufacturer.
References
- 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 3.Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- 4.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
- 5.Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge — Information for Providers (FAQs). CMS.gov. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
- 6.Aetna. Wegovy PA with Limit 4774-C P08-2025 v5 — Pharmacy Clinical Policy Bulletin (non-Medicare). Aetna. 2026. https://www.aetna.com/products/rxnonmedicare/data/2026/Wegovy_PA_with_Limit_4774-C_P08-2025_v5.html
- 7.Cigna. Drug Coverage Policy IP0816 — Zepbound (effective 09/01/2026). Cigna. 2026. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0816_coveragepositioncriteria_weight_loss_zepbound.pdf
- 8.UnitedHealthcare. Prior Authorization/Notification — Weight Loss, Program Number 2026 P 1114-23 (effective 10/1/2026). UnitedHealthcare Pharmacy. 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
- 9.Express Scripts (TRICARE pharmacy contractor). GLP-1 Medications (Diabetes and Weight Management) — TRICARE pharmacy benefit FAQ. Express Scripts / TRICARE. 2026. https://militaryrx.express-scripts.com/GLP-1-medications-diabetes-weight-management
- 10.American Medical Association. Prior Authorization Reform Initiatives and Physician Documentation Guidance. AMA. 2024. https://www.ama-assn.org/practice-management/prior-authorization
- 11.Centers for Medicare & Medicaid Services. Prior Authorization — Healthcare.gov Glossary. Healthcare.gov. 2024. https://www.healthcare.gov/glossary/prior-authorization/
- 12.Novo Nordisk. Wegovy cost, coverage and savings resources (NovoCare). Manufacturer Patient Access. 2026. https://www.novocare.com/patient/medicines/wegovy.html
Related tools and research
- Employer insurance checker — check whether your employer covers GLP-1s
- GLP-1 cost per pound lost calculator — the real cost per pound, list price against covered
Frequently Asked Questions
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
MyDrHank
An oral route if you will not self-inject
From $171/mo, prepaid
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $129/mo, prepaid
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →